Targeted Therapies for HER2-Positive Breast Cancer
For patients with HER2-positive breast cancer, the treatment landscape is replete with different older and newer types of therapies: chemotherapies such as paclitaxel and carboplatin, monoclonal antibodies such as trastuzumab and pertuzumab (with or without anthracyclines), tyrosine kinase inhibitors such as neratinib and tucatinib, and antibody-drug conjugates such as T-DM1 (ado-trastuzumab emtansine) and T-DXd (fam-trastuzumab deruxtecan-nxki). Clearly, the challenge for clinicians is which ones to use, how best to use them, and when exactly to use them.
Here is a new, informative, three-part video roundtable from JNCCN–Journal of the National Comprehensive Cancer Network to help make clinical sense of this therapeutic complexity. Join moderator Chau Dang, MD, and her expert colleagues in breast cancer Shanu Modi, MD, and Anthony D. Elias, MD, as they share their professional experience and walk viewers through the clinical considerations in therapeutic decision-making in the neoadjuvant, adjuvant, and metastatic settings in breast cancer. They also review the substantial evidence base from more than a dozen clinical trials behind such choices.
